Privately held Melinta Therapeutics Inc. had "been interested in this transaction for quite some time," Lyn Baranowski, vice president of corporate development and strategy, told BioWorld, speaking about the all-stock transaction whereby her firm will merge with a subsidiary of Cempra Inc. to create a stand-alone firm specializing in anti-infectives and trading on the NASDAQ exchange.